With a new year on the horizon and things looking up for biotech, where should one invest considering the current biotech environment?
“Cancer is a great place overall to invest in,” says health care analyst Eric Schmidt of Cowen & Co. in New York.
Many large pharmaceutical companies are bringing on their first wave of drugs to the market while others are working on second- and third-generation drugs. Be on the lookout for Propanc Health Group Corporation (PPCH) as they prepare to conduct first-in-man (FIM) studies for lead product, PRP.
“We are pleased with the progress of PRP this year, and believe we are entering an exciting growth phase for the future of the company in 2017 and beyond…”-James Nathanielsz, PPCH’s CEO Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers and have announced their plans 2017. lead product, PRP, is a solution for daily intravenous administration of pancreatic proenzymes typsinogen and chymotrypsinogen. This could transform the way the world treats cancer patients.
2016’s in R&D
Prepared and submitted four new patents relating to the dosing, anti-cancer effects and mechanisms of the two proenzymes against various cancers in Australia, Spain and the United States.
Executed a manufacturing agreement with AmatsiQBiologials in Belgium beginning the process for the finished productPRP for human use.
Completed 14-day, dose range toxicity study in rats determining maximum for further studies.
Developed an enzyme linked immunosorbent assay (ELISA) method.
Developed and validated a new IR (infrared) dye-labelled detection method for typsinogen and chymotrypsinogen.
Commenced the in-life phase of a GLP-compliant, 28-day repeat dose-toxicity study for PRP in rats, which is expected to help define the safe starting dose in advanced cancer patients for the first-in-man studies.
2016’s Success Indicate the Following 2017
Completion of the GLP-compliant, 28-day repeat-dose toxicity study in rats for PRP.
Finished product manufacture and release of an intravenous formulation of PRP for clinical trials.
Validation of the ELISA assay for the analysis of PRP in human blood plasma to measure the distribution over time in patients.
Preparation and submission of an investigational medicine product dossier (IMPD) and clinical trial application (CTA) for PRP in the UK, for FIM studies.
Commencement of FIM studies for PRP, targeting advanced cancer patients (solid tumors)
“Our expectation is, as Propanc becomes a clinical stage biopharmaceutical company, there will be opportunities to grow and expand our pipeline, as well as working towards generating revenue through partnering our lead product, PRP, which we have already initiated preliminary discussions for, and expect to further these discussions as we generate clinical trial data.” -James Nathanielsz, PPCH’s CEO
Other Biotech Companies in the News
ImmunoCellular Therapeutics, Inc. (IMUC) about a month ago announced changes to management, appointing Anthony Gringeri, PhD, as Chief Executive Officer. This week IMUC has made a major move signaling that this decision has been a success so far.
GenVec, Inc. (GNVC) shares have spiked on the heels of news January 5th, the company announced that it had entered into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting.
“This agreement provides GenVec with the foundation to establish a proprietary and differentiated program using an individual’s pulmonary endothelium as a site for protein production,” said Douglas Swirsky, president and CEO of GenVec. “Proprietary vectors from our AdenoVerse platform are well suited for the delivery of gene editing payloads and could be useful in emerging therapeutic approaches to the long-term correction of genetic disorders such as those that cause blood factor deficiencies.”
Cempara, Inc. (CEMP) present at JP Morgan’s Healthcare Conference in San Francisco. Shares have recovered leading up to this event after tumbling on news of several class action lawsuits filed last week. Investors should watch closely.
Heat Biologics, Inc. (HTBX) is another biotech Wednesday in San Francisco at the 2017 Biotech Showcase.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States